Follow-up of patients with epidermodysplasia verruciformis treated with etretinate.
Follow-up of patients with epidermodysplasia verruciformis treated with etretinate.
复制标题
用阿维A酯治疗疣状表皮发育不良患者的随访。
DOI：
10.1159/000249249
复制
发表时间：
1986
期刊：
影响因子：
--
通讯作者：
H. Wolska
中科院分区：
文献类型：
--
作者：
S. Jabłońska;S. Obalek;H. Wolska
在我们的初步报告[1]中，我们注意到3例人乳头瘤病毒3型（HPV 3）诱导的疣状表皮发育不良（EV）和1例HPV 3和潜在致癌HPV 8双重感染的病例得到改善。我们没有在仅由EV特异性HPV诱导的EV病例中应用依维A酯，尽管在感染潜在致癌性HPV的EV患者中也报告了临床改善（2，3）。然而，随访显示，etretinate对良性疣状病变的有益作用是暂时的[4]。Kowalzick和Mensing [5]报道，HPV5诱导的EV患者接受etretinate治疗6个月后，临床改善甚微。我们同意作者的观点，即由EV特异性病毒（由潜在致癌性HPV特异性病毒）诱导的EV不是这种治疗的指征。
Sir, In our preliminary report [1], we had noticed im provement in 3 cases of human papillomavirus type 3 (HPV3)-induced epidermodysplasia verruciformis (EV) and in 1case of double infection with HPV3 and a potientially oncogenic HPV8. We did not apply etretinate in EV cases induced exclusively by EV-specific HPVs, although clinical improvement was also reported in EV patients infected with potentially onco genic HPVS (2, 3]. The follow-up showed, however, that the beneficial effect of etretinate on benign warty lesions was temporary [4].Kowalzick and Mensing [5], report only little clini cal improvement after 6 months of etretinate therapy in a patient with HPV5-induced EV. We agree with the authors that EV induced by EV-specific viruses, speci fically by potentially oncogenic HPVs, is not an indica tion for this therapy.